Protocols
20 protocol(s) meet the specified criteria
Disease Site: Lung
Protocol No.TitleStatus
A081105-CIRBRandomized Study of Erlotinib Vs Observation In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Open
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
BP29889AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST MONOCLONAL ANTIBODY) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY, PART I) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN PATIENTS WITH METASTATIC SOLID TUMORSOpen
CA209-8JTRadiation and Chemotherapy With Ipilimumab Followed By Nivolumab For Patients with Stage III Unresectable NSCLCNot Open
D933QC00001ADRIATIC: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Inoperable Limited Disease SCLC Who Have Not Progressed Following Concurrent Chemoradiation TherapyNot Open
E4512-CIRBA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
EA5142-CIRBEA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersOpen
EA5163INSIGNA-CIRBA Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.Not Open
EF-25Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)Open
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
IM-202A Randomized Open-Label Multicenter Phase 1b/2 Trial Evaluating The Safety And Efficacy Of Intratumorally-Adminstered Ilixadencel In Combination With Checkpoint Inhibitor (CPI) In Advanced Cancer Therapy Subjects Who Are Candidate For CPI TherapyOpen
LCCC1626Phase Ib/II Study Of IV Nivolumab And Intrapleural Talmogene Laherparepvec For Patients With Malignant Pleural Effusion Open
LOXO-RET-17001A Phase ½ Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)Open
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
SGNTV-001Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors.Open
STU-022015-069A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)Open
TSP0147Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction PatientsOpen